hempfusion news

HempFusion Appoints Maria Leal as Chief Financial Officer

HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) ("HempFusion" or the "Company"), a leading health and wellness company offering premium probiotic supplements and products containing CBD, is pleased to announce that it has promoted Maria Leal, the Company's Vice President, Controller and Interim Chief Financial Officer, to Chief Financial Officer.

Ms. Leal holds a CPA and an MBA and has a strong track record in financial management having served in various senior financial accounting positions during her more than 20-year career. Since joining HempFusion in July of 2019, Ms. Leal has been instrumental in all financial reporting aspects for the Company.

"Having Maria continue as our full-time Chief Financial Officer will benefit HempFusion since she truly understands the business, is well connected in the industry, and knows how to navigate certain complex regulations," said Jason Mitchell, N.D., HempFusion's Co-Founder and Chief Executive officer. "Maria is an outstanding steward and strategist of capital and will play a key role in HempFusion's next phase of growth," continued Dr. Mitchell.

ABOUT HEMPFUSION

One of a select few CBD companies who are today fully prepared to meet or exceed expected FDA guidance, HempFusion Wellness Inc. is a leading health and wellness company whose family of premium consumer brands include HempFusion ™, Sagely Naturals ™, Apothecanna ™, and Probulin Probiotics ™, one of the fastest-growing probiotics companies in the United States according to SPINs reported data.

Utilizing the power of whole-food hemp nutrition, the HempFusion family of brands' product portfolio comprises 112 SKUs including USDA Organic Certified Tinctures, proprietary FDA Drug Listed Over-The-Counter (OTC) Topicals, probiotic supplements and skin care products, a Doctor/Practitioner line, a White Label division and more. With a strong focus on research and development, HempFusion Wellness has 43 products under development.

Available from more than 15,000 US retail locations across all 50 states, HempFusion Wellness products are also available in China, Mexico, Ireland, United Kingdom, United Arab Emirates, South Korea and Canada and may be purchased online from each brand's website, The Probulin Store on Amazon.com, Alibaba's Tmall.com, the world's largest cross-border online marketplace, and a multitude of additional e-commerce sites.

For more information, visit www.hempfusion.com and follow HempFusion on Twitter , Facebook and Instagram .

Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.

Investor Relations
Eric Balshin
+1 437-826-9911
eric@sophiccapital.com

Company Contact:
Jason Mitchell, N.D.
Chief Executive Officer and Director
ir@hempfusion.com

News Provided by Business Wire via QuoteMedia

The Conversation (0)
Radiopharm Theranostics

Investor Webinar – 3pm AEST Tuesday 2 July

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that CEO and Managing Director Riccardo Canevari and Executive Chairman Paul Hopper will conduct an investor webinar to provide an update following announcement of the Company’s $70 million capital raising.

When: 3pm AEST, Tuesday 2 July 2024

Keep reading...Show less
Researcher in medical lab looking at sample with microscope.

Oncology Stocks: 8 Biggest NASDAQ Companies in 2024

The wide-ranging oncology market covers every area of cancer care, from diagnosis to treatment.

Coming in only after cardiovascular disease, cancer is the second leading cause of death worldwide; unsurprisingly, oncology is one of the biggest sectors in the life science space. With that in mind, biotechnology and pharmaceutical companies alike are working to develop best-in-class therapeutics for the treatment of various cancers, including lung, breast and prostate cancer.

At this point, their work is far from finished — Fortune Business Insights projects that the global oncology market will increase at a compound annual growth rate of 11.3 percent to reach US$518.25 billion in 2032.

As the global oncology market grows, investors who want exposure to companies working to treat cancer should consider taking a look at biotech and pharma companies with a focus on oncology drugs and testing.

Keep reading...Show less
Radiopharm Theranostics

Radiopharm Theranostics Limited (ASX: RAD) – Reinstatement to Quotation

Description

The suspension of trading in the securities of Radiopharm Theranostics Limited (‘RAD’) will be lifted immediately following the release by RAD of an announcement regarding its capital raising.

Keep reading...Show less
Radiopharm Theranostics

Radiopharm Theranostics Completes A$70 Million Placement

Radiopharm Theranostics Limited (ASX:RAD), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, has received firm commitments to raise approximately A$70.0 million (before costs) by way of a placement (the Placement) comprised of international and Australian institutional and industry investors, including Lantheus Holdings (“Lantheus”) and specialist US healthcare investors.

Keep reading...Show less
Radiopharm Theranostics

Radiopharm Receives Strategic Investment for up to A$18 million

Radiopharm Theranostics Limited (ASX:RAD) (Radiopharm or the Company), a developer of diagnostic and therapeutic radiopharmaceutical products, has entered into strategic agreements with Lantheus Holdings, Inc. (LNTH.NASDAQ), a leading radiopharmaceutical-focused company, and its affiliates (Lantheus). Lantheus has agreed to make an initial equity investment of A$7.5 million (US$4.99 million) and will have an option to invest a further A$7.5 million (US$5 million) within 6 months on the same terms. Additionally, Radiopharm has agreed to transfer two of its early preclinical assets to Lantheus for A$3.0 million (US$2.0 million) pursuant to a separate transfer and development agreement.

Keep reading...Show less
Radiopharm Theranostics

Radiopharm Theranostics Limited (ASX: RAD) – Trading Halt

Description

The securities of Radiopharm Theranostics Limited (‘RAD’) will be placed in trading halt at the request of RAD, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 24 June 2024 or when the announcement is released to the market.

Keep reading...Show less

Latest Press Releases

Related News

×